Film-coated tablets containing 10 mg or 25 mg empagliflozin. Indication: Type 2 diabetes mellitus: Jardiance is indicated for the treatment of adults with insufficiently controlled Type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance; in addition to other medical products for the treatment of diabetes. For study results with respect to combinations, effects on glycemic control and cardiovascular events, and the populations studied, refer to the Summary of Product Characteristics. Heart failure: Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Dose and Administration: Type 2 diabetes mellitus: The recommended starting dose is 10 mg once daily. In patients tolerating empagliflozin 10 mg once daily who have an eGFR <60 ml/min/1.73 m² and need tighter glycemic control, the dose can be increased to 25 mg once daily. The maximum daily dose is 25 mg. Renal impairment: The glycaemic efficacy of empagliflozin is dependent on renal function. For cardiovascular risk reduction as add on to standard of care, a dose of 10 mg empagliflozin once daily should be used in patients with an eGFR below 60 ml/min/1.73 m². Because the glycaemic lowering efficacy of empagliflozin is reduced in patients with moderate renal impairment and likely absent in patients with severe renal impairment, if further glycaemic control is needed, the addition of other anti-hyperglycaemic agents should be considered. For the indication of Type 2 diabetes mellitus and established cardiovascular disease, a dose of 10 mg empagliflozin once daily should be used in patients with an eGFR below 45 ml/min/1.73 m². Because the glycaemic lowering efficacy of empagliflozin is reduced in patients with moderate renal impairment and likely absent in patients with severe renal impairment, the dose can be increased to 25 mg empagliflozin. In patients with an eGFR of 45 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min. Dose adjustment recommendations for treatment of Type 2 diabetes mellitus: For patients with an eGFR >60 ml/min/1.73 m² or CrCl >60 ml/min initiate with 10 mg empagliflozin; in patients tolerating 10 mg empagliflozin a dose of 25 mg empagliflozin can be considered in patients with an eGFR 30 to <60 ml/min/1.73 m² or CrCl <60 ml/min the daily dose of empagliflozin is limited to 10 mg. Empagliflozin is not recommended when eGFR is below 30 ml/min/1.73 m² or CrCl below 30 ml/min.